Physician profile
Jesse Andrewe Raley
NPI 1851422422
$381.70
in general payments reported to CMS, 2019-2025
14 companies · $39.46 in 2025
The $39.46 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $27.72 · 2021: $87.02 · 2022: $23.19 · 2023: $45.63 · 2025: $39.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.68 | 2019-2021 | |
| Shire North American Group INC | $44.44 | 2019 | |
| Vanda Pharmaceuticals INC. | $43.87 | 2019-2021 | |
| Tris Pharma INC | $32.38 | 2019-2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $26.28 | 2021-2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $23.86 | 2021 | |
| Axsome Therapeutics, INC. | $23.38 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.08 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $14.35 | 2019 | |
| Neos Therapeutics, Lp | $13.66 | 2023 | Cotempla Xr-Odt |
| Lundbeck LLC | $13.60 | 2019 | |
| Bausch Health US, LLC | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Raley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.